# Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina K. Singh,Terri L. Parker,Alexander Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Kenneth C. Anderson,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar |
| Citations | 259 |
| DOI | 10.1016/s1470-2045(20)30452-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/7591827 |
| OpenAlex ID | https://openalex.org/W3082053425 |
| PMID | 32866432 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Benjamin M. Parsons](https://scholariq.org/researchers/benjamin-m-parsons/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)

## Paper topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.